{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:56:55Z","timestamp":1791280615085,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"DOI":"10.1007\/s00702-026-03295-w","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:40:53Z","timestamp":1791279653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does genetic testing remain relevant in advanced Parkinson\u2019s disease?"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-6959","authenticated-orcid":false,"given":"Ana","family":"Westenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine J.","family":"Endaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"2","key":"3295_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.14802\/jmd.19080","volume":"13","author":"JO Aasly","year":"2020","unstructured":"Aasly JO (2020) Long-term outcomes of genetic Parkinson\u2019s disease. J Mov Disord 13(2):81\u201396","journal-title":"J Mov Disord"},{"key":"3295_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","volume":"78","author":"M Anheim","year":"2012","unstructured":"Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, Pollak P, Bona\u00efti B, Bona\u00efti-Pelli\u00e9 C, Brice A, French Parkinson Disease Genetic Group (2012) Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 78:417\u2013420. https:\/\/doi.org\/10.1212\/WNL.0b013e318245f476","journal-title":"Neurology"},{"issue":"12","key":"3295_CR3","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Odin PLA (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34(12):2063\u20132073. https:\/\/doi.org\/10.1080\/03007995.2018.1502165","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"3295_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40120-021-00313-9","volume":"11","author":"A Antonini","year":"2022","unstructured":"Antonini A, Pahwa R, Odin P, Henriksen T, Soileau MJ, Rodriguez-Cruz R, Isaacson SH, Merola A, Lindvall S, Domingos J, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Parra JC, Kukreja PK, Onuk K, Bergmann L, Pike J, Ray Chaudhuri K (2022) Psychometric properties of clinical indicators for identification and management of advanced Parkinson\u2019s disease: real-world evidence from G7 countries. Neurol Ther 11(1):303\u2013318. https:\/\/doi.org\/10.1007\/s40120-021-00313-9","journal-title":"Neurol Ther"},{"issue":"5","key":"3295_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/mdc3.13994","volume":"11","author":"E Asimakidou","year":"2024","unstructured":"Asimakidou E, Xiromerisiou G, Sidiropoulos C (2024) Motor and non-motor outcomes of deep brain stimulation across the genetic panorama of Parkinson\u2019s disease: a multi-scale meta-analysis. Mov Disord Clin Pract 11(5):465\u2013477. https:\/\/doi.org\/10.1002\/mdc3.13994","journal-title":"Mov Disord Clin Pract"},{"key":"3295_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106065","volume":"123","author":"S Aslam","year":"2024","unstructured":"Aslam S, Manfredsson F, Stokes A, Shill H (2024) Advanced\" Parkinson\u2019s disease: a review. Parkinsonism Relat Disord 123:106065. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106065","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"3295_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jnnp-2023-332387","volume":"95","author":"M Avenali","year":"2024","unstructured":"Avenali M, Zangaglia R, Cuconato G et al (2024) Are patients with GBA-Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort. J Neurol Neurosurg Psychiatry 95(4):309\u2013315. https:\/\/doi.org\/10.1136\/jnnp-2023-332387","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"3295_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jamaneurol.2026.1112","volume":"83","author":"A Balck","year":"2026","unstructured":"Balck A, Vollstedt EJ, Westenberger A, Lange LM, Trinh J, Kasten M, Lohmann K, Br\u00fcggemann N, Trenkwalder C, Mollenhauer B, Alcalay R, Galvelis KG, Beck JC, Bauer P, Klein C, K\u00f6nig IR, Global Parkinson\u2019s Genetics Program (GP2), ROPAD Study Group, PDGENEration Study (2026) Genetic testing by age at onset in Parkinson disease. JAMA Neurol 83(7):711\u2013713. https:\/\/doi.org\/10.1001\/jamaneurol.2026.1112","journal-title":"JAMA Neurol"},{"key":"3295_CR9","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/mds.28200","volume":"35","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Tunesi S, Tesei S, Lopiano L, Zecchinelli AL, Goldwurm S (2020) Penetrance of glucocerebrosidase (GBA) mutations in Parkinson\u2019s disease: a kin cohort study. Mov Disord 35:2111\u20132114. https:\/\/doi.org\/10.1002\/mds.28200","journal-title":"Mov Disord"},{"issue":"10","key":"3295_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(24)00323-5","volume":"23","author":"C Beetz","year":"2024","unstructured":"Beetz C, Radefeldt M, Tripolszki K, Kandaswamy KK, Bauer P, ROPAD Study Group (2024) RAB32 mutation in Parkinson\u2019s disease. Lancet Neurol 23:961. https:\/\/doi.org\/10.1016\/S1474-4422(24)00323-5","journal-title":"Lancet Neurol"},{"issue":"1","key":"3295_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ene.12022","volume":"20","author":"A Berardelli","year":"2013","unstructured":"Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M (2013) EFNS\/MDS-ES recommendations for the diagnosis of Parkinson\u2019s disease. Eur J Neurol 20(1):16\u201334. https:\/\/doi.org\/10.1111\/ene.12022","journal-title":"Eur J Neurol"},{"key":"3295_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01021","volume":"9","author":"A Book","year":"2018","unstructured":"Book A, Guella I, Candido T, Brice A, Hattori N, Jeon B, Farrer MJ, SNCA Multiplication Investigators of the GEoPD Consortium (2018) A meta-analysis of \u03b1-synuclein multiplication in familial parkinsonism. Front Neurol 9:1021. https:\/\/doi.org\/10.3389\/fneur.2018.01021","journal-title":"Front Neurol"},{"issue":"3","key":"3295_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.26071","volume":"30","author":"K Brockmann","year":"2015","unstructured":"Brockmann K, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W, Gasser T, Berg D (2015) GBA-associated Parkinson\u2019s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 30(3):407\u2013411. https:\/\/doi.org\/10.1002\/mds.26071","journal-title":"Mov Disord"},{"issue":"5","key":"3295_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","volume":"80","author":"R Cilia","year":"2016","unstructured":"Cilia R, Tunesi S, Marotta G, Cereda E, Siri C, Tesei S, Zecchinelli AL, Canesi M, Mariani CB, Meucci N, Sacilotto G, Zini M, Barichella M, Magnani C, Duga S, Asselta R, Sold\u00e0 G, Seresini A, Seia M, Pezzoli G, Goldwurm S (2016) Survival and dementia in GBA-associated Parkinson\u2019s disease: the mutation matters. Ann Neurol 80(5):662\u2013673. https:\/\/doi.org\/10.1002\/ana.24777","journal-title":"Ann Neurol"},{"issue":"7","key":"3295_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70179","volume":"32","author":"R Cilia","year":"2025","unstructured":"Cilia R, Colucci F, Cereda E et al (2025) Effects of GBA1 variants in patients with Parkinson\u2019s disease and levodopa-carbidopa intestinal gel: a nation-wide, multicenter, longitudinal, \u201creal-world\u201d study. The EPIC study. Eur J Neurol 32(7):e70179. https:\/\/doi.org\/10.1111\/ene.70179","journal-title":"Eur J Neurol"},{"key":"3295_CR16","unstructured":"ClinicalTrials.gov (2024a) A phase 1\/2a open-label ascending dose study to evaluate the safety and effects of LY3884961 in patients with Parkinson\u2019s disease with at least one GBA1 mutation (PROPEL). ClinicalTrials.gov Identifier: NCT04127578 Available at: https:\/\/clinicaltrials.gov"},{"key":"3295_CR17","unstructured":"ClinicalTrials.gov (2024b) A phase 2 study of NEU-411 in companion diagnostic-positive participants with early Parkinson\u2019s disease (NEULARK). ClinicalTrials.gov Identifier: NCT06680830 Available at: https:\/\/clinicaltrials.gov"},{"key":"3295_CR18","unstructured":"ClinicalTrials.gov (2024c) Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) (BEACON). ClinicalTrials.gov Identifier: NCT06602193 Available at: https:\/\/clinicaltrials.gov"},{"key":"3295_CR19","unstructured":"ClinicalTrials.gov (2024d) A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 (LUMA). ClinicalTrials.gov Identifier: NCT05348785 Available at: https:\/\/clinicaltrials.gov"},{"issue":"5","key":"3295_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135633","volume":"6","author":"TA Cole","year":"2021","unstructured":"Cole TA, Zhao H, Collier TJ, Sandoval I, Sortwell CE, Steece-Collier K, Daley BF, Booms A, Lipton J, Welch M, Berman M, Jandreski L, Graham D, Weihofen A, Celano S, Schulz E, Cole-Strauss A, Luna E, Quach D, Mohan A, Paumier KL (2021) \u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease. JCI Insight 6(5):e135633. https:\/\/doi.org\/10.1172\/jci.insight.135633","journal-title":"JCI Insight"},{"issue":"2","key":"3295_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000535","volume":"5","author":"F Colucci","year":"2023","unstructured":"Colucci F, Avenali M, De Micco R, Fusar Poli M, Cerri S, Stanziano M, Bacila A, Cuconato G, Franco V, Franciotta D, Ghezzi C, Gastaldi M, Elia AE, Romito L, Devigili G, Leta V, Garavaglia B, Golfr\u00e8 Andreasi N, Cazzaniga F, Reale C, Cilia R (2023) Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson\u2019s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol. BMJ Neurol Open 5(2):e000535. https:\/\/doi.org\/10.1136\/bmjno-2023-000535","journal-title":"BMJ Neurol Open"},{"issue":"1","key":"3295_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1212\/CPJ.0000000000000831","volume":"11","author":"L Cook","year":"2021","unstructured":"Cook L, Schulze J, Kopil C, Hastings T, Naito A, Wojcieszek J, Payne K, Alcalay RN, Klein C, Saunders-Pullman R, Simuni T, Foroud T (2021) Genetic testing for Parkinson disease: are we ready? Neurol Clin Pract 11(1):69\u201377. https:\/\/doi.org\/10.1212\/CPJ.0000000000000831","journal-title":"Neurol Clin Pract"},{"issue":"8","key":"3295_CR24","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/brain\/awae142","volume":"147","author":"L Cook","year":"2024","unstructured":"Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Foroud T, Hall A, Marder KS, Mata IF, Mencacci NE, Nance MA, Schwarzschild MA, Simuni T, Bressman S, Wills AM, Fernandez HH, Litvan I, Lyons KE, Shill HA, Singer C, Tropea TF et al (2024) Parkinson\u2019s disease variant detection and disclosure: PD GENEration, a North American study. Brain 147(8):2668\u20132679. https:\/\/doi.org\/10.1093\/brain\/awae142","journal-title":"Brain"},{"issue":"5","key":"3295_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mdc3.12795","volume":"6","author":"LM de Oliveira","year":"2019","unstructured":"de Oliveira LM, Barbosa ER, Aquino CC, Munhoz RP, Fasano A, Cury RG (2019) Deep brain stimulation in patients with mutations in Parkinson\u2019s disease-related genes: a systematic review. Mov Disord Clin Pract 6(5):359\u2013368. https:\/\/doi.org\/10.1002\/mdc3.12795","journal-title":"Mov Disord Clin Pract"},{"issue":"7","key":"3295_CR26","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/mds.29346","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer JM, Kruithof AC, Moerland M, Walker M, Dudgeon L, Justman C, Solomini I, Splitalny L, Leymarie N, Khatri K, Cullen VC, Hilt DC, Groeneveld GJ, Lansbury P (2023) A phase 1B trial in GBA1-associated Parkinson\u2019s disease of BIA-28-6156, a glucocerebrosidase activator. Mov Disord 38(7):1197\u20131208. https:\/\/doi.org\/10.1002\/mds.29346","journal-title":"Mov Disord"},{"key":"3295_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107127","volume":"128","author":"JM Fern\u00e1ndez-Vidal","year":"2024","unstructured":"Fern\u00e1ndez-Vidal JM, Aracil-Bola\u00f1os I, Garc\u00eda-S\u00e1nchez C, Campolongo A, Curell M, Rodr\u00edguez-Rodriguez R, Aibar-Duran J\u00c1, Kulisevsky J, Pascual-Sedano B (2024) Cognitive phenotyping of GBA1-Parkinson\u2019s disease: a study on deep brain stimulation outcomes. Parkinsonism Relat Disord 128:107127. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107127","journal-title":"Parkinsonism Relat Disord"},{"key":"3295_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/1877718X261452868","volume":"16","author":"V Flores-Ocampo","year":"2026","unstructured":"Flores-Ocampo V, Zirra A, Tay YW, van Midden V, Mata IF, Noyce AJ, Peri\u00f1an MT, Global Parkinson\u2019s Genetics Program (GP2) (2026) The Global Parkinson\u2019s Genetics Program (GP2): advancing genetic discovery and capacity building worldwide. J Parkinsons Dis 16:617\u2013628. https:\/\/doi.org\/10.1177\/1877718X261452868","journal-title":"J Parkinsons Dis"},{"key":"3295_CR29","doi-asserted-by":"publisher","first-page":"3494609","DOI":"10.1155\/2019\/3494609","volume":"2019","author":"A Fraint","year":"2019","unstructured":"Fraint A, Ouyang B, Metman LV, Jones C, Hall DA, Marder K, Pal G (2019) Patient knowledge and attitudes towards genetic testing in Parkinson\u2019s disease subjects with deep brain stimulation. Park Dis 2019:3494609. https:\/\/doi.org\/10.1155\/2019\/3494609","journal-title":"Park Dis"},{"issue":"8","key":"3295_CR30","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/brain\/awae181","volume":"147","author":"Z Gan-Or","year":"2024","unstructured":"Gan-Or Z (2024) Clinical genetic testing in Parkinson\u2019s disease should become part of routine patient care. Brain 147(8):2595\u20132597. https:\/\/doi.org\/10.1093\/brain\/awae181","journal-title":"Brain"},{"key":"3295_CR31","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","volume":"84","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Amshalom I, Kilarski LL, Bar-Shira A, Gana-Weisz M, Mirelman A, Marder K, Bressman S, Giladi N, Orr-Urtreger A (2015) Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 84:880\u2013887. https:\/\/doi.org\/10.1212\/WNL.0000000000001315","journal-title":"Neurology"},{"issue":"8","key":"3295_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi N, Alcalay RN, Cutter G et al (2023) Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 22(8):661\u2013671. https:\/\/doi.org\/10.1016\/S1474-4422(23)00205-3","journal-title":"Lancet Neurol"},{"key":"3295_CR33","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/mds.28494","volume":"36","author":"Global Parkinson\u2019s Genetics Program","year":"2021","unstructured":"Global Parkinson\u2019s Genetics Program (2021) GP2: The Global Parkinson\u2019s Genetics Program. Mov Disord 36:842\u2013851. https:\/\/doi.org\/10.1002\/mds.28494","journal-title":"Mov Disord"},{"key":"3295_CR34","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/ana.78180","volume":"99","author":"A Hach","year":"2026","unstructured":"Hach A, Lohmann K, Funayama M, Menon PJ, Vollstedt EJ, Kleinz T, Yoshino H, Lesage S, Meier B, Sue CM, Corvol JC, Brice A, Hattori N, Klein C, Rakovic A (2026) Alternative translation initiation in PRKN delays the onset of Parkinson\u2019s disease and offers a therapeutic target. Ann Neurol 99:1379\u20131393. https:\/\/doi.org\/10.1002\/ana.78180","journal-title":"Ann Neurol"},{"key":"3295_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00569-y","volume":"9","author":"M Hackl","year":"2023","unstructured":"Hackl M, Cook L, Wetherill L, Walsh LE, Delk P, De Le\u00f3n R, Carbonell J, Cruz Vicioso R, Delgado Hodges P (2023) Readiness for Parkinson\u2019s disease genetic testing and counseling in patients and their relatives in urban settings in the Dominican Republic. npj Parkinsons Dis 9:126. https:\/\/doi.org\/10.1038\/s41531-023-00569-y","journal-title":"npj Parkinsons Dis"},{"issue":"7","key":"3295_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","volume":"7","author":"DG Healy","year":"2008","unstructured":"Healy DG, Falchi M, O\u2019Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW, International LRRK2 Consortium (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study. Lancet Neurol 7(7):583\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(08)70117-0","journal-title":"Lancet Neurol"},{"issue":"6","key":"3295_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1212\/WNL.0000000000000675","volume":"83","author":"F Hentati","year":"2014","unstructured":"Hentati F, Trinh J, Thompson C, Nosova E, Farrer MJ, Aasly JO (2014) LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. Neurology 83(6):568\u2013569. https:\/\/doi.org\/10.1212\/WNL.0000000000000675","journal-title":"Neurology"},{"key":"3295_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-026-00599-0","author":"T Hioki","year":"2026","unstructured":"Hioki T, Nishimura M, Sun X, Jacobo SM, Nakayama M, Nishihara M, Tohyama K, Liu PT, Okai T, Tanaka M, Proetzel G (2026) In vitro and in vivo rescue of dopaminergic neurons in Parkinson\u2019s disease models after Parkin gene therapy. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-026-00599-0","journal-title":"Gene Ther"},{"key":"3295_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.14802\/jmd.23023","volume":"16","author":"YE Huh","year":"2023","unstructured":"Huh YE, Usnich T, Scherzer CR, Klein C, Chung SJ (2023) GBA1 variants and Parkinson\u2019s disease: Paving the way for targeted therapy. J Mov Disord 16:261\u2013278. https:\/\/doi.org\/10.14802\/jmd.23023","journal-title":"J Mov Disord"},{"issue":"7","key":"3295_CR40","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(08)70116-9","volume":"7","author":"MM Hulihan","year":"2008","unstructured":"Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, Prinjha RK, Upmanyu R, Kefi M, Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ (2008) LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 7(7):591\u2013594. https:\/\/doi.org\/10.1016\/S1474-4422(08)70116-9","journal-title":"Lancet Neurol"},{"issue":"648","key":"3295_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, Maloney MT, Propson NE, Zhu Y, Maciuca RD, Harris L, Kay A, LeWitt P, King TA, Kern D, Troyer MD (2022) Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med 14(648):eabj2658. https:\/\/doi.org\/10.1126\/scitranslmed.abj2658","journal-title":"Sci Transl Med"},{"issue":"3","key":"3295_CR42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, Diaz D, Goo MS, Chen JJ, Maciuca R, Fraser K, Mabrouk OS, van de Wetering de Rooij J, Heuberger JAAC, Groeneveld GJ, Borin MT, Cruz-Herranz A, Graham D, Scearce-Levie K, De Vicente J, Henry AG, Chin P, Ho C, Troyer MD (2023) LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson\u2019s disease. Mov Disord 38(3):386\u2013398. https:\/\/doi.org\/10.1002\/mds.29297","journal-title":"Mov Disord"},{"issue":"4","key":"3295_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mds.27971","volume":"35","author":"S Ji","year":"2020","unstructured":"Ji S, Wang C, Qiao H, Gu Z, Gan-Or Z, Fon EA, Chan P (2020) Decreased penetrance of Parkinson\u2019s disease in elderly carriers of glucocerebrosidase gene L444P\/R mutations: a community-based 10-year longitudinal study. Mov Disord 35(4):672\u2013678. https:\/\/doi.org\/10.1002\/mds.27971","journal-title":"Mov Disord"},{"key":"3295_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105853","volume":"117","author":"SD Kamath","year":"2023","unstructured":"Kamath SD, Holla VV, Kamble N, Yadav R, Pal PK (2023) Genetic literacy and attitude towards genetic testing in patients with Parkinson\u2019s disease and their caregivers: a review of literature. Parkinsonism Relat Disord 117:105853. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105853","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"3295_CR45","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/mds.27352","volume":"33","author":"M Kasten","year":"2018","unstructured":"Kasten M, Hartmann C, Hampf J, Schaake S, Westenberger A, Vollstedt EJ, Balck A, Domingo A, Vulinovic F, Dulovic M, Zorn I, Madoev H, Zehnle H, Lembeck CM, Schawe L, Reginold J, Huang J, K\u00f6nig IR, Bertram L, Marras C, Klein C (2018) Genotype-phenotype relations for the Parkinson\u2019s disease genes Parkin, PINK1, DJ1: MDSGene systematic review. Mov Disord 33(5):730\u2013741. https:\/\/doi.org\/10.1002\/mds.27352","journal-title":"Mov Disord"},{"key":"3295_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-49969-7_2","volume":"14","author":"M Kestenbaum","year":"2017","unstructured":"Kestenbaum M, Alcalay RN (2017) Clinical features of LRRK2 carriers with Parkinson\u2019s disease. Adv Neurobiol 14:31\u201348. https:\/\/doi.org\/10.1007\/978-3-319-49969-7_2","journal-title":"Adv Neurobiol"},{"key":"3295_CR47","unstructured":"Kleinz T, Br\u00fcggemann N, Klein C (2026) PRKN-related early-onset Parkinson disease. In: Adam MP, Bick S, Mirzaa GM, (eds) GeneReviews\u00ae [Internet]. University of Washington, Seattle, Seattle, WA. Updated 30 June 2026. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1478\/"},{"issue":"12","key":"3295_CR48","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/acn3.70176","volume":"12","author":"AM Kmiecik","year":"2025","unstructured":"Kmiecik AM et al (2025) Genetic modifiers of Parkinson\u2019s disease: a case\u2013control study. Ann Clin Transl Neurol 12(12):2482\u20132494. https:\/\/doi.org\/10.1002\/acn3.70176","journal-title":"Ann Clin Transl Neurol"},{"key":"3295_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00881-9","volume":"11","author":"C Kr\u00fcger","year":"2025","unstructured":"Kr\u00fcger C, Lim SY, Buhrmann A, Fahrig FL, Gabbert C, Bahr N, Madoev H, Marras C, Klein C, Lohmann K (2025) Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson\u2019s disease. npj Parkinsons Dis 11:30. https:\/\/doi.org\/10.1038\/s41531-025-00881-9","journal-title":"npj Parkinsons Dis"},{"key":"3295_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.nrl.2013.05.001","volume":"28","author":"J Kulisevsky","year":"2013","unstructured":"Kulisevsky J, Luquin M, Arbelo J, Burguera J, Carrillo F, Castro A et al (2013) Advanced Parkinson\u2019s disease: clinical characteristics and treatment (part 1). Neurologia 28:503\u201321","journal-title":"Neurologia"},{"key":"3295_CR100","doi-asserted-by":"publisher","unstructured":"Kuusim\u00e4ki T, Korpela J, Pekkonen E, Martikainen MH, Antonini A, Kaasinen V (2020) Deep brain stimulation for monogenic Parkinson's disease: a systematic review. J Neurol 267(4):883\u2013897. https:\/\/doi.org\/10.1007\/s00415-019-09181-8","DOI":"10.1007\/s00415-019-09181-8"},{"issue":"5","key":"3295_CR51","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, Graham DL, Sapir I, SPARK Investigators (2022) Trial of cinpanemab in early Parkinson\u2019s disease. N Engl J Med 387(5):408\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa2203395","journal-title":"N Engl J Med"},{"issue":"5","key":"3295_CR52","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/mds.28982","volume":"37","author":"LM Lange","year":"2022","unstructured":"Lange LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, Ebrahimi-Fakhari D, Gabbert C, Ganos C, Ghosh R, Kumar KR, Lang AE, Rossi M, van der Veen S, van de Warrenburg B, Warner T, Lohmann K, Klein C, Marras C, Task Force on Genetic Nomenclature in Movement Disorders (2022) Nomenclature of genetic movement disorders: recommendations of the International Parkinson and Movement Disorder Society Task Force\u2014an update. Mov Disord 37(5):905\u2013935. https:\/\/doi.org\/10.1002\/mds.28982","journal-title":"Mov Disord"},{"issue":"4","key":"3295_CR53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMc055540","volume":"354","author":"S Lesage","year":"2006","unstructured":"Lesage S, D\u00fcrr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A, French Parkinson\u2019s Disease Genetics Study Group (2006) LRRK2 G2019S as a cause of Parkinson\u2019s disease in North African Arabs. N Engl J Med 354(4):422\u2013423. https:\/\/doi.org\/10.1056\/NEJMc055540","journal-title":"N Engl J Med"},{"key":"3295_CR54","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ana.24781","volume":"80","author":"G Liu","year":"2016","unstructured":"Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR, International Genetics of Parkinson Disease Progression (IGPP) Consortium (2016) Specifically neuropathic Gaucher\u2019s mutations accelerate cognitive decline in Parkinson\u2019s. Ann Neurol 80:674\u2013685. https:\/\/doi.org\/10.1002\/ana.24781","journal-title":"Ann Neurol"},{"issue":"4","key":"3295_CR55","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/ana.78139","volume":"99","author":"MA Loeffler","year":"2026","unstructured":"Loeffler MA, Klocke P, Wurster I, Lerche S, Cebi I, Gasser T, Gharabaghi A, Brockmann K, Weiss D (2026) Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation. Ann Neurol 99(4):976\u2013988. https:\/\/doi.org\/10.1002\/ana.78139","journal-title":"Ann Neurol"},{"issue":"4","key":"3295_CR56","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-014-0288-8","volume":"11","author":"K Lohmann","year":"2014","unstructured":"Lohmann K, Klein C (2014) Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics 11(4):699\u2013707. https:\/\/doi.org\/10.1007\/s13311-014-0288-8","journal-title":"Neurotherapeutics"},{"key":"3295_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4047392","author":"MR Luquin","year":"2017","unstructured":"Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES (2017) Consensus on the definition of advanced Parkinson\u2019s disease: a neurologists-based Delphi study (CEPA study). Parkinsons Dis. https:\/\/doi.org\/10.1155\/2017\/4047392","journal-title":"Parkinsons Dis"},{"issue":"10","key":"3295_CR58","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/mds.28238","volume":"35","author":"T L\u00fcth","year":"2020","unstructured":"L\u00fcth T, K\u00f6nig IR, Gr\u00fcnewald A, Kasten M, Klein C, Hentati F, Farrer M, Trinh J (2020) Age at onset of LRRK2 p.Gly2019Ser is related to environmental and lifestyle factors. Mov Disord 35(10):1854\u20131858. https:\/\/doi.org\/10.1002\/mds.28238","journal-title":"Mov Disord"},{"issue":"4","key":"3295_CR59","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3233\/JPD-171172","volume":"7","author":"V Lythe","year":"2017","unstructured":"Lythe V, Athauda D, Foley J, Mencacci NE, Jahanshahi M, Cipolotti L, Hyam J, Zrinzo L, Hariz M, Hardy J, Limousin P, Foltynie T (2017) GBA-associated Parkinson\u2019s disease: progression in a deep brain stimulation cohort. J Parkinsons Dis 7(4):635\u2013644. https:\/\/doi.org\/10.3233\/JPD-171172","journal-title":"J Parkinsons Dis"},{"key":"3295_CR60","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41591-026-04262-4","volume":"32","author":"OS Mabrouk","year":"2026","unstructured":"Mabrouk OS, Tichler B, Arnold HM et al (2026) LRRK2-targeting antisense oligonucleotide in Parkinson\u2019s disease: a phase 1 randomized controlled trial. Nat Med 32:1421\u20131431. https:\/\/doi.org\/10.1038\/s41591-026-04262-4","journal-title":"Nat Med"},{"issue":"5","key":"3295_CR61","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s10897-018-0239-3","volume":"27","author":"KA Maloney","year":"2018","unstructured":"Maloney KA, Alaeddin DS, von Coelln R et al (2018) Parkinson\u2019s disease: patients\u2019 knowledge, attitudes, and interest in genetic counseling. J Genet Couns 27(5):1200\u20131209. https:\/\/doi.org\/10.1007\/s10897-018-0239-3","journal-title":"J Genet Couns"},{"key":"3295_CR62","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.expneurol.2007.06.019","volume":"207","author":"FP Manfredsson","year":"2007","unstructured":"Manfredsson FP, Burger C, Sullivan LF, Muzyczka N, Lewin AS, Mandel RJ (2007) rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson\u2019s disease. Exp Neurol 207:243\u2013252. https:\/\/doi.org\/10.1016\/j.expneurol.2007.06.019","journal-title":"Exp Neurol"},{"issue":"1","key":"3295_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1212\/WNL.0000000000001708","volume":"85","author":"K Marder","year":"2015","unstructured":"Marder K, Wang Y, Alcalay RN, Mejia-Santana H, Tang MX, Lee A, Raymond D, Mirelman A, Saunders-Pullman R, Clark L, Ozelius L, Orr-Urtreger A, Giladi N, Bressman S, LRRK2 Ashkenazi Jewish Consortium (2015) Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 85(1):89\u201395. https:\/\/doi.org\/10.1212\/WNL.0000000000001708","journal-title":"Neurology"},{"issue":"4","key":"3295_CR64","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1212\/WNL.0b013e318227042d","volume":"77","author":"C Marras","year":"2011","unstructured":"Marras C, Sch\u00fcle B, Munhoz RP et al (2011) Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 77(4):325\u2013333. https:\/\/doi.org\/10.1212\/WNL.0b013e318227042d","journal-title":"Neurology"},{"issue":"1","key":"3295_CR66","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41531-024-00677-3","volume":"10","author":"PJ Menon","year":"2024","unstructured":"Menon PJ, Sambin S, Crini\u00e8re-Boizet B et al (2024) Genotype-phenotype correlation in PRKN-associated Parkinson\u2019s disease. NPJ Parkinsons Dis 10(1):72. https:\/\/doi.org\/10.1038\/s41531-024-00677-3","journal-title":"NPJ Parkinsons Dis"},{"key":"3295_CR67","unstructured":"Morris H, Lim SY (2025) Monogenic Parkinson disease overview. In: Adam MP, Bick S, Mirzaa GM, (eds) GeneReviews\u00ae [Internet]. University of Washington, Seattle, Seattle, WA.\u00a0Updated 15 May 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/"},{"issue":"4","key":"3295_CR68","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K, D\u2019Souza G, Woodgate P, Elflein J, H\u00e4llqvist J, Toffoli M, Streeter A, Hosking J, Heywood WE, Khengar R, Campbell P, Hehir J, Cable S, Mills K, Zetterberg H, Limousin P, Libri V, Foltynie T, Schapira AHV (2020) Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol 77(4):427\u2013434. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4611","journal-title":"JAMA Neurol"},{"key":"3295_CR69","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fneur.2020.00527","volume":"11","author":"DA Olszewska","year":"2020","unstructured":"Olszewska DA, McCarthy A, Soto-Beasley AI, Walton RL, Magennis B, McLaughlin RL, Hardiman O, Ross OA, Lynch T (2020) Association between glucocerebrosidase mutations and Parkinson\u2019s disease in Ireland. Front Neurol 11:527. https:\/\/doi.org\/10.3389\/fneur.2020.00527","journal-title":"Front Neurol"},{"issue":"4","key":"3295_CR70","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMc055540","volume":"354","author":"LJ Ozelius","year":"2006","unstructured":"Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB (2006) LRRK2 G2019S as a cause of Parkinson\u2019s disease in Ashkenazi Jews. N Engl J Med 354(4):424\u2013425. https:\/\/doi.org\/10.1056\/NEJMc055540","journal-title":"N Engl J Med"},{"issue":"5","key":"3295_CR71","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, L\u00f3pez-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Prasinezumab Study Group (2022) Trial of prasinezumab in early-stage Parkinson\u2019s disease. N Engl J Med 387(5):421\u2013432. https:\/\/doi.org\/10.1056\/NEJMoa2202867","journal-title":"N Engl J Med"},{"issue":"8","key":"3295_CR72","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/mds.29500","volume":"38","author":"G Pal","year":"2023","unstructured":"Pal G, Cook L, Schulze J, Verbrugge J, Alcalay RN, Merello M, Sue CM, Bardien S, Bonifati V, Chung SJ, Foroud T, Gatto E, Hall A, Hattori N, Lynch T, Marder K, Mascalzoni D, Novakovi\u0107 I, Thaler A, Raymond D, Klein C (2023a) Genetic testing in Parkinson\u2019s disease. Mov Disord 38(8):1384\u20131396. https:\/\/doi.org\/10.1002\/mds.29500","journal-title":"Mov Disord"},{"issue":"12","key":"3295_CR73","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/mds.29647","volume":"38","author":"GD Pal","year":"2023","unstructured":"Pal GD, Corcos DM, Metman LV, Israel Z, Bergman H, Arkadir D (2023b) Cognitive effects of subthalamic nucleus deep brain stimulation in Parkinson\u2019s disease with GBA1 pathogenic variants. Mov Disord 38(12):2155\u20132162. https:\/\/doi.org\/10.1002\/mds.29647","journal-title":"Mov Disord"},{"key":"3295_CR74","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/mds.29314","volume":"38","author":"SC Parlar","year":"2023","unstructured":"Parlar SC, Grenn FP, Kim JJ, Blauwendraat C, Gan-Or Z (2023) Classification of GBA1 variants in Parkinson\u2019s disease: The GBA1-PD Browser. Mov Disord 38:489\u2013495. https:\/\/doi.org\/10.1002\/mds.29314","journal-title":"Mov Disord"},{"issue":"6","key":"3295_CR75","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1159\/000540873","volume":"102","author":"FA Ponce","year":"2024","unstructured":"Ponce FA, Shill HA (2024) What is advanced Parkinson\u2019s disease? Defining what determines Medicare coverage for deep brain stimulation in the USA. Stereotact Funct Neurosurg 102(6):414\u2013419. https:\/\/doi.org\/10.1159\/000540873","journal-title":"Stereotact Funct Neurosurg"},{"key":"3295_CR76","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/mds.30041","volume":"40","author":"M Radefeldt","year":"2025","unstructured":"Radefeldt M, Lemke S, Chaichoompu K, Paul JJ, Curado F, Valzania F, Cavallieri F, Fioravanti V, Valente EM, Avenali M, Negrotti A, Hanagasi HA, Thonke S, Matarazzo M, Panzavolta A, Cerami C, Westenberger A, Klein C, Bauer P, Beetz C (2025) Genetic and epidemiological insights into RAB32-linked Parkinson\u2019s disease. Mov Disord 40:147\u2013151. https:\/\/doi.org\/10.1002\/mds.30041","journal-title":"Mov Disord"},{"key":"3295_CR77","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/gim.2012.107","volume":"15","author":"HQ Rana","year":"2013","unstructured":"Rana HQ, Balwani M, Bier L, Alcalay RN (2013) Age-specific Parkinson disease risk in GBA mutation carriers: Information for genetic counseling. Genet Med 15:146\u2013149. https:\/\/doi.org\/10.1038\/gim.2012.107","journal-title":"Genet Med"},{"issue":"11","key":"3295_CR78","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(23)00283-1","volume":"22","author":"M Rizig","year":"2023","unstructured":"Rizig M, Bandres-Ciga S, Makarious MB, Ojo OO, Crea PW, Abiodun OV, Levine KS, Abubakar SA, Achoru CO, Vitale D, Adeniji OA, Agabi OP, Koretsky MJ, Agulanna U, Hall DA, Akinyemi RO, Xie T, Ali MW, Shamim EA, Ani-Osheku I, Global Parkinson\u2019s Genetics Program (2023) Identification of genetic risk loci and causal insights associated with Parkinson\u2019s disease in African and African admixed populations: a genome-wide association study. Lancet Neurol 22(11):1015\u20131025. https:\/\/doi.org\/10.1016\/S1474-4422(23)00283-1","journal-title":"Lancet Neurol"},{"key":"3295_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120354","volume":"440","author":"M Rossi","year":"2022","unstructured":"Rossi M, Castillo-Torres SA, Merello M (2022) Early motor response to dopamine replacement therapy in Parkinson\u2019s disease patients carrying GBA variants. J Neurol Sci 440:120354. https:\/\/doi.org\/10.1016\/j.jns.2022.120354","journal-title":"J Neurol Sci"},{"key":"3295_CR80","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/mds.30141","volume":"40","author":"M Rossi","year":"2025","unstructured":"Rossi M, Schaake S, Usnich T, Boehm J, Steffen N, Schell N, Kr\u00fcger C, G\u00fcl-Demirkale T, Bahr N, Kleinz T, Madoev H, Laabs BH, Gan-Or Z, Alcalay RN, Lohmann K, Klein C (2025) Classification and genotype\u2013phenotype relationships of GBA1 variants: MDSGene systematic review. Mov Disord 40:605\u2013618. https:\/\/doi.org\/10.1002\/mds.30141","journal-title":"Mov Disord"},{"key":"3295_CR101","doi-asserted-by":"publisher","unstructured":"Salles PA, Liao J, Shuaib U, Mata IF, Fernandez HH (2022) A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies. J Parkinsons Dis 12(6):1703\u20131725. https:\/\/doi.org\/10.3233\/JPD-212986","DOI":"10.3233\/JPD-212986"},{"key":"3295_CR81","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7537924","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda D, de Deus Fonticoba T, Su\u00e1rez Castro E, Aneiros D\u00edaz A, McAfee D (2020) 5-2-1 criteria: a simple screening tool for identifying advanced PD patients who need an optimization of Parkinson\u2019s treatment. Parkinsons Dis. https:\/\/doi.org\/10.1155\/2020\/7537924","journal-title":"Parkinsons Dis"},{"key":"3295_CR82","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fnins.2019.00273","volume":"13","author":"J Sassone","year":"2019","unstructured":"Sassone J, Valtorta F, Ciammola A (2019) Early dyskinesias in Parkinson\u2019s disease patients with Parkin mutation: a primary corticostriatal synaptopathy? Front Neurosci 13:273. https:\/\/doi.org\/10.3389\/fnins.2019.00273","journal-title":"Front Neurosci"},{"issue":"19","key":"3295_CR83","doi-asserted-by":"publisher","first-page":"e2037","DOI":"10.1212\/WNL.0000000000009400","volume":"94","author":"E Schaeffer","year":"2020","unstructured":"Schaeffer E, Rogge A, Nieding K, Helmker V, Letsch C, Hauptmann B, Berg D (2020) Patients\u2019 views on the ethical challenges of early Parkinson disease detection. Neurology 94(19):e2037\u2013e2044. https:\/\/doi.org\/10.1212\/WNL.0000000000009400","journal-title":"Neurology"},{"issue":"2","key":"3295_CR84","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12687-013-0168-7","volume":"5","author":"TM Scuffham","year":"2014","unstructured":"Scuffham TM, McInerny-Leo A, Ng SK, Mellick G (2014) Knowledge and attitudes towards genetic testing in those affected with Parkinson\u2019s disease. J Community Genet 5(2):167\u2013177. https:\/\/doi.org\/10.1007\/s12687-013-0168-7","journal-title":"J Community Genet"},{"key":"3295_CR99","doi-asserted-by":"publisher","unstructured":"Senkevich K, Rudakou U, Gan-Or Z (2022) New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Neuropharmacology. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108822","DOI":"10.1016\/j.neuropharm.2021.108822"},{"key":"3295_CR85","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fnagi.2018.00283","volume":"10","author":"L Shu","year":"2018","unstructured":"Shu L, Zhang Y, Pan H, Xu Q, Guo J, Tang B, Sun Q (2018) Clinical heterogeneity among LRRK2 variants in Parkinson\u2019s disease: a meta-analysis. Front Aging Neurosci 10:283. https:\/\/doi.org\/10.3389\/fnagi.2018.00283","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"3295_CR86","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/jnnp-2020-322857","volume":"91","author":"TB Stoker","year":"2020","unstructured":"Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T, Evans J, Breen DP, Barker RA, Williams-Gray CH (2020) Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 91(7):695\u2013703","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"3295_CR87","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5603\/pjnns.107157","volume":"60","author":"S Szlufik","year":"2026","unstructured":"Szlufik S, Jaros K, Milanowski \u0141, Mandat T, Koziorowski D (2026) Adding continuous infusion therapies after bilateral subthalamic deep brain stimulation in advanced Parkinson\u2019s disease: clinical outcomes and quality of life assessment in a case series. Neurol Neurochir Pol 60(3):300\u2013309. https:\/\/doi.org\/10.5603\/pjnns.107157","journal-title":"Neurol Neurochir Pol"},{"issue":"3","key":"3295_CR88","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.neulet.2005.04.103","volume":"384","author":"EK Tan","year":"2005","unstructured":"Tan EK, Shen H, Tan LCS, Farrer M, Yew K, Chua E, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yih Y, Skipper L, Liu JJ (2005) The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson\u2019s disease patients. Neurosci Lett 384(3):327\u2013329. https:\/\/doi.org\/10.1016\/j.neulet.2005.04.103","journal-title":"Neurosci Lett"},{"issue":"2","key":"3295_CR89","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jns.2006.10.016","volume":"252","author":"EK Tan","year":"2007","unstructured":"Tan EK, Lee J, Hunter C, Shinawi L, Fook-Chong S, Jankovic J (2007) Comparing knowledge and attitudes towards genetic testing in Parkinson\u2019s disease in an American and Asian population. J Neurol Sci 252(2):113\u2013120. https:\/\/doi.org\/10.1016\/j.jns.2006.10.016","journal-title":"J Neurol Sci"},{"key":"3295_CR90","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.parkreldis.2018.05.009","volume":"55","author":"A Thaler","year":"2018","unstructured":"Thaler A, Bregman N, Gurevich T, Shiner T, Dror Y, Zmira O, Gan-Or Z, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A (2018) Parkinson\u2019s disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism Relat Disord 55:45\u201349. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.05.009","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"3295_CR91","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00415-026-13683-7","volume":"273","author":"M Toffoli","year":"2026","unstructured":"Toffoli M, Menozzi E, Cullen M, Chowdhury K, Ahmed S, Freemantle N, Duffen J, Wyse RK, Stott SRW, Matthews H, Dexter D, Ikeji F, Moss J, Watts P, Foltynie T, Kieburtz K, Rascol O, Poewe W, Schapira AHV (2026) Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson\u2019s disease. J Neurol 273(2):151. https:\/\/doi.org\/10.1007\/s00415-026-13683-7","journal-title":"J Neurol"},{"issue":"12","key":"3295_CR92","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/mds.27527","volume":"33","author":"J Trinh","year":"2018","unstructured":"Trinh J, Zeldenrust FMJ, Huang J, Kasten M, Schaake S, Petkovic S, Madoev H, Gr\u00fcnewald A, Almuammar S, K\u00f6nig IR, Lill CM, Lohmann K, Klein C, Marras C (2018) Genotype-phenotype relations for the Parkinson\u2019s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 33(12):1857\u20131870. https:\/\/doi.org\/10.1002\/mds.27527","journal-title":"Mov Disord"},{"issue":"1","key":"3295_CR93","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1474-4422(25)00305-9","volume":"25","author":"J Trinh","year":"2026","unstructured":"Trinh J, de Vries NM, Chan P, Dekker MCJ, Helmich RC, Bloem BR (2026) The role of lifestyle interventions in symptom management and disease modification in Parkinson\u2019s disease. Lancet Neurol 25(1):90\u2013102. https:\/\/doi.org\/10.1016\/S1474-4422(25)00305-9","journal-title":"Lancet Neurol"},{"issue":"1","key":"3295_CR94","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/mdc3.70290","volume":"13","author":"IAD Vico","year":"2026","unstructured":"Vico IAD, Gallo S, Bertoncello E, Ledda C, Tinazzi M, Lopiano L, Artusi CA (2026) The influence of genetics in the early development of axial postural abnormalities in Parkinson\u2019s disease. Mov Disord Clin Pract 13(1):230\u2013235. https:\/\/doi.org\/10.1002\/mdc3.70290","journal-title":"Mov Disord Clin Pract"},{"key":"3295_CR95","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1002\/mds.30006","volume":"39","author":"SRL Vieira","year":"2024","unstructured":"Vieira SRL, Mezabrovschi R, Toffoli M, Del Pozo SL, Menozzi E, Mullin S, Yalkic S, Limbachiya N, Koletsi S, Loefflad N, Lopez GJ, Gan-Or Z, Alcalay RN, Sidransky E, Schapira AHV (2024) Consensus guidance for genetic counseling in GBA1 variants: a focus on Parkinson\u2019s disease. Mov Disord 39:2144\u20132154. https:\/\/doi.org\/10.1002\/mds.30006","journal-title":"Mov Disord"},{"issue":"2","key":"3295_CR96","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/mds.29288","volume":"38","author":"EJ Vollstedt","year":"2023","unstructured":"Vollstedt EJ, Schaake S, Lohmann K, Padmanabhan S, Brice A, Lesage S, Tesson C, Vidailhet M, Wurster I, Hentati F, Mirelman A, Giladi N, Marder K, Waters C, Fahn S, Kasten M, Br\u00fcggemann N, Borsche M, Foroud T, Tolosa E et al (2023) Embracing monogenic Parkinson\u2019s disease: the MJFF Global Genetic PD Cohort. Mov Disord 38(2):286\u2013303. https:\/\/doi.org\/10.1002\/mds.29288. MJFF Global Genetic Parkinson\u2019s Disease Study Group","journal-title":"Mov Disord"},{"issue":"8","key":"3295_CR97","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1093\/brain\/awae188","volume":"147","author":"A Westenberger","year":"2024","unstructured":"Westenberger A, Skrahina V, Usnich T et al (2024) Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson\u2019s disease study. Brain 147(8):2652\u20132667. https:\/\/doi.org\/10.1093\/brain\/awae188","journal-title":"Brain"},{"issue":"7","key":"3295_CR98","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041774","volume":"15","author":"A Westenberger","year":"2025","unstructured":"Westenberger A, Br\u00fcggemann N, Klein C (2025) Genetics of Parkinson\u2019s disease: from causes to treatment. Cold Spring Harb Perspect Med 15(7):a041774. https:\/\/doi.org\/10.1101\/cshperspect.a041774","journal-title":"Cold Spring Harb Perspect Med"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03295-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03295-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03295-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:40:55Z","timestamp":1791279655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03295-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":99,"alternative-id":["3295"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03295-w","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"10 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}